Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature.
Sign Up to like & getrecommendations! Published in 2022 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202207_29287
Abstract: BACKGROUND Glioblastoma (GBM) is a highly lethal disease despite integrated treatment comprising radiotherapy plus concomitant and adjuvant temozolomide, with a median overall survival of less than 15 months. For recurrent glioblastoma, there is yet no… read more here.
Keywords: glioblastoma; response regorafenib; case report; regorafenib early ... See more keywords